title: Changes in midwall systolic performance and cardiac hypertrophy reduction in hypertensive patients.
abstract: OBJECTIVE
  To investigate changes in left ventricular (LV) performance, as evaluated by measurement of midwall LV fractional shortening (FS), after reduction of cardiac hypertrophy.
  
  
  METHODS
  Echocardiographic evaluation of LV anatomy and function was performed by M-mode echocardiography at baseline, after long-term antihypertensive therapy, and after treatment withdrawal in 68 asymptomatic hypertensive patients (50 males, 18 females, age range 22-62 years). Patients were divided according to the presence of LV hypertrophy (LVH) at baseline (LV mass index, LVMI, > or = 51 g/m(2.7)).
  
  
  RESULTS
  At baseline patients with concentric (relative wall thickness > 0.44) LV hypertrophy (n = 38) or remodelling (n = 7) had reduced midwall shortening with respect to patients with normal LV geometry (n = 4) or eccentric LVH (n = 19); no differences were observed for endocardial FS. After long-term treatment (average 15 months), in 11 patients LV mass remained within normal limits, in 45 patients LVH reduction was obtained, while in 12 patients LV mass remained persistently elevated. Midwall FS was significantly increased in patients with reduction of LVH both during treatment and after withdrawal of treatment, while it remained significantly lower in patients with persistently elevated LV mass. Changes in midwall fractional shortening were independently associated with modifications in relative wall thickness (P < 0.00001), with changes in end-diastolic dimensions (P < 0.0001) and those of LVMI (P< 0.02) as shown by multivariate analysis.
  
  
  CONCLUSIONS
  LV midwall systolic performance significantly improved after reduction of LVH, even in the presence of high blood pressure values. Modifications in relative wall thickness are more independently associated with changes, in LV diastolic dimensions and mass, to midwall improvement
authors.affiliation: Department of Medical and Surgical Sciences, Internal Medicine, University of Brescia, Italy. muiesan@master.cci.unibs.it
authors.forename: M L
authors.initials: ML
authors.lastname: Muiesan
authors.forename: M
authors.initials: M
authors.lastname: Salvetti
authors.forename: C
authors.initials: C
authors.lastname: Monteduro
authors.forename: D
authors.initials: D
authors.lastname: Rizzoni
authors.forename: C
authors.initials: C
authors.lastname: Corbellini
authors.forename: M
authors.initials: M
authors.lastname: Castellano
authors.forename: E
authors.initials: E
authors.lastname: Porteri
authors.forename: E
authors.initials: E
authors.lastname: Agabiti-Rosei
mesh_terms: D000328:Adult; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D004452:Echocardiography; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology*; D017379:Hypertrophy, Left Ventricular / Q000150:complications / Q000000981:diagnostic imaging / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D012044:Regression Analysis; D013599:Systole / Q000502:physiology*
chemical_list: D000959:Antihypertensive Agents